Eloxx Pharmaceuticals (ELOX) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on small molecule therapies that modulate the ribosome to promote readthrough of nonsense mutations (NMs), targeting rare genetic diseases affecting kidney and skin.

• Lead candidate exaluren is being developed for Alport syndrome with nonsense mutations (NMAS) and autosomal dominant polycystic kidney disease (ADPKD) with NMs.

• ZKN-013, an oral ribosome modulating agent, is licensed to Almirall for rare skin diseases, including recessive dystrophic and junctional epidermolysis bullosa.

• Pipeline leverages ribosome modulation for diseases with high unmet need, with a focus on rare and ultra-rare indications.

Financial performance and metrics

• Reported net losses of $6.0M (2025), $3.1M (2024), and $17.1M (2023); accumulated deficit of $304.3M as of March 31, 2026.

• License and service revenue of $6.4M in 2024 from Almirall; no product sales to date.

• Cash and cash equivalents of $6.4M as of March 31, 2026; working capital of $60.6M pro forma for the offering.

• Operating expenses primarily driven by R&D and G&A, with R&D at $3.1M (2025) and G&A at $3.4M (2025).

Use of proceeds and capital allocation

• Estimated net proceeds of $54.2M from the offering, assuming a midpoint price of $11.00 per share.

• $13.2M allocated to exaluren Phase 2b trial in NMAS; $19.2M to exaluren Phase 2 trial in nmADPKD; remainder for working capital and general corporate purposes.

• Proceeds expected to fund operations into mid-2028 based on current plans.